Log in

Relevant bibliographies by topics / Lenalidomide and pomalidomide

Contents

Journal articles
Dissertations / Theses
Conference papers

Academic literature on the topic 'Lenalidomide and pomalidomide'

Author: Grafiati

Published: 4 June 2021

Last updated: 10 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Lenalidomide and pomalidomide.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Lenalidomide and pomalidomide"

1

Lopez-Girona, Antonia, Derek Mendy, Karen Miller, et al. "Direct Binding with Cereblon Mediates the Antiproliferative and Immunomodulatory Action of Lenalidomide and Pomalidomide." Blood 118, no. 21 (2011): 738. http://dx.doi.org/10.1182/blood.v118.21.738.738.

Full text

Abstract:

Abstract Abstract 738 Thalidomide, lenalidomide and pomalidomide are therapeutically active in a number of hematological malignant and premalignant conditions including myelodysplastic syndromes, multiple myeloma, and lymphomas. Clinical efficacy is ascribed to a complement of overlapping activities including direct antitumor effects, immune system activation and inhibition of stromal support of tumor growth. Thalidomide has previously been shown to bind cereblon (CRBN) a protein required for the teratogenic effects of thalidomide in zebrafish and chicken embryos (Ito et al). CRBN forms an ubi

APA, Harvard, Vancouver, ISO, and other styles

2

Lacy, Martha Q., and Arleigh R. McCurdy. "Pomalidomide." Blood 122, no. 14 (2013): 2305–9. http://dx.doi.org/10.1182/blood-2013-05-484782.

Full text

Abstract:

Abstract This spotlight review focuses on the second-generation immunomodulatory drug pomalidomide, which was recently approved by the US Food and Drug Administration. This drug was approved for patients with multiple myeloma who have received at least 2 prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of the last therapy. This review focuses on the clinical trial data that led to approval and provides advice for treating physicians who are now prescribing this drug for patients.

APA, Harvard, Vancouver, ISO, and other styles

3

Sinha, Shirshendu, Shaji Kumar, Suzanne Hayman, et al. "Response to Salvage Therapies and Outcome of Patients with Multiple Myeloma Relapsing After Pomalidomide Therapy." Blood 116, no. 21 (2010): 1965. http://dx.doi.org/10.1182/blood.v116.21.1965.1965.

Full text

Abstract:

Abstract Abstract 1965 Background: Pomalidomide is an immunomodulatory compound to be used for heavily pre-treated patients with relapse and refractory multiple myeloma and has shown considerable efficacy in recent clinical trials. It is not clear how patients may respond to other therapies, once the disease becomes refractory to pomalidomide. We examined this question among a cohort of patients receiving pomalidomide therapy in phase 2 clinical trials. Methods: Patients enrolled in an ongoing phase 2 clinical trial of pomalidomide (2-4 mg daily) along with dexamethasone (40 mg weekly), in rel

APA, Harvard, Vancouver, ISO, and other styles

4

Kastritis, Efstathios, Maria Roussou, Maria Gavriatopoulou, et al. "Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone." Blood Advances 3, no. 23 (2019): 4095–103. http://dx.doi.org/10.1182/bloodadvances.2019000539.

Full text

Abstract:

Key Points There was no significant difference in response rates, PFS, or OS among patients that developed resistance to different lenalidomide doses. Longer duration of prior lenalidomide and a longer lenalidomide-free interval are associated with better outcomes with pomalidomide.

APA, Harvard, Vancouver, ISO, and other styles

5

Bartlett, J. B., L. Wu, M. Adams, P. Schafer, G. Muller, and D. Stirling. "Lenalidomide and pomalidomide strongly enhance tumor cell killing in vitro during antibody-dependent cellular cytotoxicity (ADCC) mediated by trastuzumab, cetuximab and rituximab." Journal of Clinical Oncology 25, no. 18_suppl (2007): 3023. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.3023.

Full text

Abstract:

3023 Background: Potential mechanisms of action of lenalidomide and pomalidomide (CC-4047) include anti-angiogenic, anti- proliferative and immunomodulatory activities, e.g., enhancement of T cell and NK cell function. Both drugs appear to enhance T cell activation and Th1-type cytokines in cancer patients. Also, both drugs have been shown to enhance rituximab-mediated protection in a mouse lymphoma model. Methods: We have utilized an in vitro ADCC system to assess the ability of these drugs to enhance human NK cell function in response to the approved therapeutic antibodies trastuzumab, cetux

APA, Harvard, Vancouver, ISO, and other styles

6

Rekhtina, I. G., and L. P. Mendeleeva. "Efficiency of pomalidomide therapy in patients with multiple myeloma refractory to lenalidomide." Oncohematology 14, no. 1 (2019): 8–13. http://dx.doi.org/10.17650/1818-8346-2019-14-1-8-13.

Full text

Abstract:

Currently, there has been a marked increase in the number of opportunities for relapsed and refractory multiple myeloma treatment due toemergence of new target drugs. These include pomalidomide, a 3rd generation immunomodulator capable of treating double refractory multiple myeloma (to lenalidomide and bortezomib). Efficacy and safety of pomalidomide combined with low doses of dexamethasone have beenestablished in MM-003 and STRATUS trials. The summary presents the data on opportunities to further enhance the efficacy of pomalidomide combined with other antitumor drugs in patients with relapse

APA, Harvard, Vancouver, ISO, and other styles

7

Siegel, David S., Gary J. Schiller, Christy Samaras, et al. "Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment." Leukemia 34, no. 12 (2020): 3286–97. http://dx.doi.org/10.1038/s41375-020-0813-1.

Full text

Abstract:

AbstractPatients with multiple myeloma who have relapsed after or become refractory to lenalidomide in early treatment lines represent a clinically important population in need of effective therapies. The safety and efficacy of pomalidomide, low-dose dexamethasone, and daratumumab was evaluated in lenalidomide-pretreated patients with relapsed or refractory multiple myeloma (RRMM) after one to two prior treatment lines in the phase 2 MM-014 study. Patients received pomalidomide 4 mg daily from days 1–21 and dexamethasone 40 mg weekly (28-day cycles). Daratumumab 16 mg/kg was administered per l

APA, Harvard, Vancouver, ISO, and other styles

8

Phan, Vien, Tomoki Ito, Muneo Inaba, et al. "Immunomodulatory drugs suppress Th1-inducing ability of dendritic cells but enhance Th2-mediated allergic responses." Blood Advances 4, no. 15 (2020): 3572–85. http://dx.doi.org/10.1182/bloodadvances.2019001410.

Full text

Abstract:

Abstract Immunomodulatory drugs (IMiDs), lenalidomide and pomalidomide, are widely used treatments for multiple myeloma; however, they occasionally lead to episodes of itchy skin and rashes. Here, we analyzed the effects of IMiDs on human myeloid dendritic cells (mDCs) as major regulators of Th1 or Th2 responses and the role they play in allergy. We found that lenalidomide and pomalidomide used at clinical concentrations did not affect the survival or CD86 and OX40-ligand expression of blood mDCs in response to lipopolysaccharide (LPS) and thymic stromal lymphopoietin (TSLP) stimulation. Both

APA, Harvard, Vancouver, ISO, and other styles

9

Leleu, Xavier, Michel Attal, Bertrand Arnulf, et al. "Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02." Blood 121, no. 11 (2013): 1968–75. http://dx.doi.org/10.1182/blood-2012-09-452375.

Full text

Abstract:

Key Points Combination of pomalidomide with dexamethasone is highly active and can salvage end stage myeloma refractory to lenalidomide and bortezomib. Current data suggest pomalidomide 4 mg/day on days 1 to 21 per 28-days cycle with dexmethasone should be studied in future phase 3 trials.

APA, Harvard, Vancouver, ISO, and other styles

10

Bolzoni, Marina, Manuela Abeltino, Paola Storti, et al. "The Immunomodulatory Drugs Lenalidomide and Pomalidomide Inhibit Multiple Myeloma-Induced Osteoclast Formation and RANKL/OPG Ratio In Myeloma Microenvironment Targeting the Expression of Adhesion Molecules." Blood 116, no. 21 (2010): 448. http://dx.doi.org/10.1182/blood.v116.21.448.448.

Full text

Abstract:

Abstract Abstract 448 The increase of osteoclast formation and activation occurring into the bone marrow (BM) area of myeloma cells infiltration is the hallmark of multiple myeloma (MM). The increase of the RANKL/OPG ratio in BM stromal cells (BMSCs) and osteoprogenitor cells, induced by MM cells through the cell-to-cell contact, is critically involved in MM-induced osteoclast formation. In addition, MM cells also up-regulate RANKL expression and secretion by activated T in the MM BM microenvironment. Soluble factors such as CCL3/MIP-1α, IL-3 and IL-7 produced by MM cells contribute to the inc

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Lenalidomide and pomalidomide"

1

Jiang, Yao. "PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES OF LENALIDOMIDE AND POMALIDOMIDE." The Ohio State University, 2015. http://rave.ohiolink.edu/etdc/view?acc_num=osu1429830196.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Yu, Helen. "Subunit Selective Degradation of WIZ, a Lenalidomide- and Pomalidomide-Dependent Substrate of E3 Ubiquitin Ligase CRL4CRBN." Thesis, 2019. https://thesis.library.caltech.edu/11485/2/yu-helen-2019-thesis.pdf.

Full text

Abstract:

<p>This dissertation is focused on identifying novel targets of immunomodulatory(IMiD) drugs. IMiDs are a class of drugs that are used to treat multiple myeloma.The first chapter is an introduction to the clinical use of IMiDs, as well as the proteincereblon (CRBN), the primary target of IMiDs. The second chapter describes worktowards the identification of a novel IMiD target, WIZ, that is regulated by CRBNin an IMiD dependent manner. Mass spectrometry was performed to identify novelbinding partners, and IMiD dependent regulation by CRBN was validated usingchemical and genetic methods. Underst

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Lenalidomide and pomalidomide"

1

Das, Rituparna, Kartik Sehgal, Lin Zhang, et al. "Abstract 1354: Comparison of pomalidomide dosing strategies in lenalidomide-refractory myeloma: Impact on clinical outcome, immune activation and cereblon targets." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-1354.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

De Oca, Rocio Montes, Ira Gupta, and Chris Shelton. "Abstract 6711: Combinations of belantamab mafodotin with lenalidomide, pomalidomide, bortezomib and/or dexamethasone synergizein vitroand potentiatein vivoanti-tumor activity in multiple myeloma." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-6711.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Gopan, Gayatri, Geetha Narayanan, Sreejith G. Nair, et al. "Outcome of Treatment in Elderly Myeloma—A Single-Centre Experience." In Annual Conference of Indian Society of Medical and Paediatric Oncology (ISMPO). Thieme Medical and Scientific Publishers Pvt. Ltd., 2021. http://dx.doi.org/10.1055/s-0041-1735368.

Full text

Abstract:

Abstract Introduction Multiple myeloma (MM) accounts for approximately 1% of all cancers and 10% of all hematologic malignancies. In our institution, we see around 200 patients with myeloma every year. We present our experience with multiple myeloma in the patients aged more than 60 years. Objectives This is a retrospective study of 300 newly diagnosed multiple myeloma patients above 60 years of age treated in the Department of Medical Oncology, Regional Cancer Center, Thiruvananthapuram, Kerala, India, during the period between 2014 and 2017. The medical records of the patients were studied a

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!